United States Liquid Biopsy Market (by Circulating Biomarker, Product, Application, Cancer Types, Non-Cancer Application, End User, Clinical Application, Sample Type), Initiatives, Funding, Major Deals, Company Profiles, and Recent Developments - Forecast to 2031

The United States liquid biopsy market was valued at around US$ 1,200 Million in 2023, and the market is projected to reach US$ 3,807 Million by 2031. Liquid biopsy tests are executed to understand the molecular aspects of cancer across healthcare and research settings, such as hospitals, physicians, and pathological and research laboratories. Cancer is the second leading cause of death in the United States, and the increasing incidence of cancer is becoming a critical health challenge. According to the National Cancer Institute, in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. In order to address the growing cancer burden, numerous cancer research organizations are actively adopting innovative strategies and patient-centered approaches for early diagnosis and treatment of cancer.

For many years, tissue biopsy has been considered the gold standard for cancer diagnosis. However, the limitations associated with this invasive procedure, such as discomfort, pain and risk of complications have hindered the wide acceptance of this technique for cancer diagnosis. Over time, extensive research on liquid biopsy has resulted in its recognition as a viable technique for cancer detection. The advantages of liquid biopsy over solid tumor biopsy, the rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel market growth over the forecast period.

The liquid biopsy market is a rapidly growing sector with numerous companies focusing on scientific advancements. For instance, in November 2023, Illumina Inc. announced TruSight Oncology 500 ctDNA v2, an advanced iteration of its liquid biopsy assay designed for comprehensive genomic profiling in oncology. This upgraded version promises enhanced sensitivity and specificity in detecting cancer-associated mutations from circulating tumor DNA. Further, in November 2023, Foundation Medicine, Inc., and Pierre Fabre Laboratories announced a collaboration to develop Foundation Medicine’s high-quality genomic tests, FoundationOne CDx and FoundationOne Liquid CDx, as companion diagnostics for new targeted therapies to treat patients with non-small cell lung cancer (NSCLC).

Recent Developments

In February 2024, Veracyte, Inc. acquired C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform and expanding the company’s ability to serve patients across the cancer care continuum.

In November 2023, Foundation Medicine, Inc., and Pierre Fabre Laboratories announced a collaboration to develop Foundation Medicine’s high-quality genomic tests, FoundationOne CDx and FoundationOne Liquid CDx, as companion diagnostics for new targeted therapies to treat patients with non-small cell lung cancer (NSCLC).

In July 2023, MiRXES raised US$ 50 Million in series D venture funding for the development and commercialization of liquid biopsy products targeting colorectal cancer and the multi-cancer early detection test.

In May 2023, Labcorp, a leading global life sciences company, launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for patients with advanced or metastatic solid tumors.

By Circulating Biomarker: United States Liquid Biopsy Market and Forecast - Key Takeaways

Based on circulating biomarkers, in 2023, the circulating tumor cells (CTCs) segment captured the largest share of the United States liquid biopsy market, followed by the circulating tumor DNA (ctDNA). The ability to early assessment of patient prognosis and providing valuable information to make a clinical decision is driving the growth of the CTCs segment in the liquid biopsy market.

The cfDNA is a non-invasive screening test used to help detect graft rejection, identify mutations in cancer patients and detect various chromosomal abnormalities in the foetus, in order to know the gender of foetus. The discovery of cfDNA has opened new potentials in the field of oncology, gynaecology, transplantation, and infectious diseases.

The extracellular vesicles (EVs) is the fastest-growing segment in the circulating biomarkers market.

By Products: United States Liquid Biopsy Market and Forecast - Key Takeaways

Based on product, the Kits and Consumables segment accounted for largest share of the liquid biopsy market. The increase in basic research and commercial applications of liquid biopsy, the increase in demand for liquid biopsy tests, and the need for reliable and specific assays are expected to drive the market growth.

The instruments segment is likely to witness the highest growth in the United States liquid biopsy market. Instruments help the experts to precisely find circulating tumor cells and circulating tumor DNA, in the blood. Many advanced and automatic instruments are adopted by laboratories and healthcare facilities globally, leading to foster the liquid biopsy market.

By Application: United States Liquid Biopsy Market and Forecast - Key Takeaways

Based on application, the cancer segment accounted for largest share of the United States liquid biopsy market. Lung cancer and breast cancer captured the highest share of the liquid biopsy oncology market. The increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications is driving the growth of this market.

The non-cancer application is expected to be the fastest-growing segment in the market over the forecast period, owing to the growing application in non-invasive prenatal testing (NIPT), using cell-free DNA assays in the identification of trisomies (which includes 13, 16, and 18), gender identification, and other genetic abnormalities such as monosomy X and microdeletions.

By Clinical Application: United States Liquid Biopsy Oncology Market and Forecast - Key Takeaways

In terms of clinical application, the therapy selection segment accounted for the largest share of the liquid biopsy market. This is due to the ability of therapy selection to detect advanced-stage cancers (stage III and IV), followed by increasing studies on liquid biopsy and advancements made in this field to also aid in the detection of early-stage cancers.

Recurrence monitoring captured the least share of the United States liquid biopsy market. Recurrence monitoring liquid biopsies routinely monitor patient after cancer treatment and detect changes in the concentration of cancer-related mutations vs. a baseline.

By End User: United States Liquid Biopsy Market and Forecast - Key Takeaways

Reference laboratories form the largest and fastest-growing end-user segment of the United States liquid biopsy market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories.

Hospital and Physician laboratories occupied nearly 30% share of the United States liquid biopsy market in 2023.

By Sample Type: United States Liquid Biopsy Market and Forecast - Key Takeaways

Blood is the most widely used sample type and is expected to remain the largest market based on sample type in the coming years as well, since most of the tests currently available in the market are blood-based tests.

The urine sample segment is anticipated to witness noticeable growth over the forecast period.

This report provides a comprehensive assessment of the fast-evolving, high-growth Liquid Biopsy Market.

This 545 Pages report with 76 Figures and 5 Tables has been analyzed from 14 viewpoints:

1. United States Liquid Biopsy Market & Forecast (2018 - 2031)
2. United States Liquid Biopsy Market Share & Forecast (2018 - 2031)
3. United States Liquid Biopsy Market & Forecast - by Circulating Biomarker (2018 - 2031)
4. United States Liquid Biopsy Market & Forecast - by Product (2018 - 2031)
5. United States Liquid Biopsy Market & Forecast - by Application (2018 - 2031)
6. United States Liquid Biopsy Oncology Market & Forecast - By Cancer Types (2018 - 2031)
7. United States Liquid Biopsy Non-Cancer Application Market & Forecast - By Types (2018 - 2031)
8. United States Liquid Biopsy Oncology Market & Forecast - by Clinical Application (2018 - 2031)
9. United States Liquid Biopsy Market & Forecast - by End User (2018 - 2031)
10. United States Liquid Biopsy Market & Forecast - by Sample Type (2018 - 2031)
11. Liquid Biopsy Initiatives
12. Liquid Biopsy Companies Financing Details
13. Company Profiles - Recent Developments / Initiatives, Major Deals
14. Liquid Biopsy Market - Driving Factors & Challenges

By Circulating Biomarker: United States Liquid Biopsy Market and Forecast

1. Circulating Tumor Cells (CTCs)
2. Circulating Tumor DNA (ctDNA)
3. Cell-Free DNA (cfDNA)
4. Extracellular Vesicles (EVs)
5. Other Circulating Biomarkers

By Product: United States Liquid Biopsy Market and Forecast

1. Kits and Consumables
2. Instruments
3. Services

By Application: United States Liquid Biopsy Market and Forecast

1. Oncology Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Gastrointestinal Cancer
• Leukaemia
• Others

2. Non-Cancer Application

• Non-Invasive Prenatal Testing (NIPT)
• Organ Transplantation
• Infectious Disease Testing

By Clinical Application: United States Liquid Biopsy Market and Forecast

1. Therapy Selection
2. Treatment Monitoring
3. Early Cancer Screening
4. Recurrence Monitoring

By End User: United States Liquid Biopsy Market and Forecast

1. Reference Laboratories
2. Hospitals and Physician Laboratories
3. Academic and Research Centers
4. Other End Users

By Sample Type: United States Liquid Biopsy Market and Forecast

1. Blood Sample
2. Urine Sample
3. Other Fluids Sample

Liquid Biopsy Market - Company Profiles, Recent Developments, Major Deals

1. Personal Genome Diagnostics (Acquired by Labcorp)
2. Guardant Health, Inc.
3. Pathway Genomics (Now OME CARE)
4. RainDance Technologies (Acquired by Bio-Rad Laboratories, Inc.)
5. Cardiff Oncology (Previously Trovagene, Inc.)
6. LungLife AI (Formerly Cynvenio Biosystems, Inc.)
7. Biocept, Inc.
8. ANGLE plc
9. MDxHealth
10. Biolidics Limited (Formerly Clearbridge Biomedics Pte Ltd)
11. Exosome Diagnostics, Inc. (Acquired by Bio-Techne Corporation)
12. Foundation Medicine, Inc
13. Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
14. Genomic Health (Now Part of Exact Sciences Corp)
15. Myriad Genetics, Inc
16. Thermo Fisher Scientific, Inc
17. QIAGEN NV
18. Bio-Rad Laboratories, Inc
19. Menarini-Silicon Biosystems
20. GRAIL
21. NeoGenomics, Inc.
22. DiaCarta, Inc.
23. OncoCell MDx (Now Immunis.AI)
24. C2i Genomics (Acquired by Veracyte, Inc.)
25. Biodesix
26. Freenome
27. Inivata
28. CellMax Life
29. Rarecyte Inc.
30. Saga Diagnostics
31. Thrive Earlier Detection Corp. (Acquired by Exact Sciences Corp.)
32. Lucence Diagnostics Pte Ltd
33. Karius, Inc.
34. Clinical Genomics Technologies Pty Ltd (CG)
35. Elypta

Data Sources

The publisher employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from the Proprietary Information Database, Primary and Secondary Research Methodologies, and In-house analysis, a dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interviews, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Reports, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.